USA

Under the definitive agreement, KKR will acquire all outstanding shares of Integer Holdings for US$127 per share in cash.

The transaction is subject to customary closing conditions, including regulatory approvals, and is expected to close in the fourth quarter of 2026.

The decision follows the failure of the phase 3 Lagoon trial, which did not meet its primary endpoint of overall survival.

The test could also help clinicians identify patients who are unlikely to benefit from immunotherapy before treatment begins, potentially allowing them to consider alternative therapies sooner.

DeepHealth Breast Ultrasound automates several stages of breast ultrasound examinations, including lesion detection, characterisation and reporting.

CereVasc designed the facility to meet the company’s expected operational needs as it advances the eShunt System towards potential commercialisation.

The latest milestone advances the company’s second clinical-stage therapeutic candidate and marks the first clinical programme built using its proprietary Au-HALO™ liver-targeting delivery technology and siRNA platform.

AbCellera will oversee discovery and early-stage development activities, while Vertex will finance all research and development costs.

Amylyx developed the education initiative after researching the PBH patient community.

eyonis LCS is a Software as a Medical Device that uses AI to assist clinicians in detecting and diagnosing lung cancer during screening workflows.